InsiderTrades

Form 4 for HRMY Harmony Biosciences Holdings, Inc.

Accepted 2022-08-23 00:00:00 ET · period of report 2022-08-22 · accession 0001415889-22-008969 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
D 2022-08-23 2022-08-22 HRMY Dierks Jeffrey Chief COMMERCIAL Off M - OptEx $24.00 +29.0K 29.0K New +$695.3K
DM 2022-08-23 2022-08-22 HRMY Dierks Jeffrey Chief COMMERCIAL Off S - Sale+OE $47.00 -29.0K 2,321 -93% -$1.36M
D 2022-08-23 2022-08-22 HRMY Dierks Jeffrey Chief COMMERCIAL Off M - OptEx $0.00 -29.0K 86.9K -25% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2022-08-22 M A 28,971 $24.00 28,971 D — —
2 Common Common Stock 2022-08-22 S D 2,321 $47.56 0 D — — (F3) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.41 to $47.70. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
3 Common Common Stock 2022-08-22 S D 26,650 $46.95 2,321 D — — (F2) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.40 to $47.39. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
4 Derivative Stock Option 2022-08-22 M D 28,971 $0.00 86,914 D $24.00 · — to 2030-08-18 28,971 Common Stock (F5) The Form 4 filed by the reporting person on March 2, 2022, overstated the number of securities owned following the reported transaction by 200 shares. The amount of securities reported herein reflects the correct number of securities owned following the transactions reported on this Form 4. (F4) The stock option vests in five equal annual installments beginning on August 21, 2021.